Data from Stressing the Development of Small Molecules Targeting HSP90
Year: 2023
Type: other
Abstract: Inhibitors of the molecular chaperone HSP90 have been in clinical development as anticancer agents since 1999. Recent clinical studies, including the work of Saif and colleagues in this issue of Clinical Cancer Research, demonstrate that significant progress has been made in overcoming the obstacles preventing regulatory approval. Clin Cancer Res; 20(2); 275–7. ©2013 AACR.
Authors: Len Neckers, Jane B. Trepel
Language: English
Topic: Heat shock proteins research
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361944064